peptibase
Weight Loss

Eloralintide

Also known as: GSBR-1290, Structure GSBR-1290

Clinical Trials
Share:

Key Facts: Eloralintide

Category
Weight Loss
FDA Status
Not FDA Approved
Clinical Status
Phase 2 - Actively enrolling Phase 3 trials for obesity
Administration
Oral tablet
Typical Dose
120-240mg once daily (oral)
Frequency
Once daily
Duration
36 weeks in Phase 2 trials
Also Known As
GSBR-1290, Structure GSBR-1290

Mechanism of Action

Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion.

Research Summary

Phase 2 GSBR-1290-004 trial (2024) showed up to 14.4% body weight reduction at 36 weeks with the highest dose. Results showed a favorable GI tolerability profile compared to injectable GLP-1 agonists, with lower rates of nausea and vomiting. The oral small-molecule design eliminates the need for injections, potentially improving patient adherence. Structure Therapeutics reported positive Phase 2b results with dose-dependent weight loss across multiple cohorts.

Trial Progress:Phase III
Pre
I
II
III
IV
FDA

Dosing Information

Phase 2 Clinical Trial·Demonstrated efficacy in controlled Phase 2 trials

Typical Dosingⓘ

Community experience

Common Dose

120-240mg once daily (oral)

Range

120-240mg per day

Frequency

Once daily

Oral small-molecule GLP-1 agonist. No injection required. Phase 2 trial doses only. Longer half-life may support less frequent dosing in future formulations.

Research Dosingⓘ

Scientific studies

Doses from clinical trials only - not yet approved

Duration

36 weeks in Phase 2 trials

Administration

Oral tablet

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Nausea (lower incidence than injectable GLP-1s)
  • ●Diarrhea
  • ●Vomiting
  • ●Constipation
  • ●Decreased appetite
  • ●Abdominal discomfort
  • ●Limited long-term safety data (Phase 2 only)

References

Research This Peptide Further

PubMedClinicalTrials.govFDA.gov

Frequently Asked Questions

What does Eloralintide do?

A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.

How does Eloralintide work?

Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion.

Is Eloralintide FDA approved?

No, Eloralintide is not currently FDA approved. Current status: Phase 2 - Actively enrolling Phase 3 trials for obesity

What are the side effects of Eloralintide?

Reported side effects include: Nausea (lower incidence than injectable GLP-1s), Diarrhea, Vomiting, Constipation, Decreased appetite. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Eloralintide?

Community-reported common dose: 120-240mg once daily (oral) (Once daily). Range: 120-240mg per day. Administration: Oral tablet. Clinical trial doses only. Not yet approved. Not medical advice.

Related Peptides

Peptides commonly compared with Eloralintide or used in similar applications.

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

Survodutide

Clinical Trials

A dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.

Weight Loss

Cagrilintide

Clinical Trials

A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).

Weight Loss

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Orforglipron

FDA

An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.

Weight Loss
How to Use EloralintideEloralintide AlternativesCompare with SimilarBrowse All Peptides

Want updates on Eloralintide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides